Emerging role of engineered exosomes in nonalcoholic fatty liver disease

被引：1
|
作者：
Ding, Jian [1 ]
Xu, Chen [1 ]
Xu, Ming [1 ]
He, Xiao-Yue [2 ]
Li, Wei-Na [3 ]
He, Fei [4 ,5 ]
机构：
[1] Fourth Mil Med Univ, Xi Jing Hosp, Dept Hepatobiliary Surg, Xian 710032, Shaanxi, Peoples R China
[2] Jining Med Univ, Affiliated Hosp Jining Med Univ, Jining 272067, Shandong, Peoples R China
[3] Fourth Mil Med Univ, Sch Basic Med, Xian 710032, Shaanxi, Peoples R China
[4] Xi Jing Hosp, Dept Hepatobiliary Surg, Xian 710032, Shaanxi, Peoples R China
[5] Xi Jing Hosp, Dept Hepatobiliary Surg, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China
来源：
WORLD JOURNAL OF HEPATOLOGY | 2023年 / 15卷 / 03期
基金：
中国国家自然科学基金;
关键词：
Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Exosome; Engineered exosome; Targeted therapy; HEPATOCELLULAR-CARCINOMA; DELIVERY; FIBROSIS; THERAPY;
D O I：
10.4254/wjh.v15.i3.386
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. NAFLD comprises a continuum of liver abnormalities from nonalcoholic fatty liver to nonalcoholic steatohepatitis, and can even lead to cirrhosis and liver cancer. However, a well-established treatment for NAFLD has yet to be identified. Exosomes have become an ideal drug delivery tool because of their high transmissibility, low immunogenicity, easy accessibility and targeting. Exosomes with specific modifications, known as engineered exosomes, have the potential to treat a variety of diseases. Here, we review the treatment of NAFLD with engineered exosomes and the potential use of exosomes as biomarkers and therapeutic targets for NAFLD.
引用
收藏
页码：386 / 392
页数：7
相关论文
共 50 条
  • [41] Mechanisms of Disease:: adipocytokines and visceral adipose tissue -: emerging role in nonalcoholic fatty liver disease
    Schäffler, A
    Schölmerich, J
    Büchler, C
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2005, 2 (06): : 273 - 280
  • [42] The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease
    Polyzos, S. A.
    Kountouras, J.
    Deretzi, G.
    Zavos, C.
    Mantzoros, C. S.
    CURRENT MOLECULAR MEDICINE, 2012, 12 (01) : 68 - 82
  • [43] Nonalcoholic fatty liver disease
    Erickson, Sandra K.
    JOURNAL OF LIPID RESEARCH, 2009, 50 : S412 - S416
  • [44] Nonalcoholic fatty liver disease
    Mach, Tomasz
    PRZEGLAD GASTROENTEROLOGICZNY, 2007, 2 (02): : 101 - 105
  • [45] The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Kazankov, Konstantin
    Jorgensen, Simon Mark Dahl
    Thomsen, Karen Louise
    Moller, Holger Jon
    Vilstrup, Hendrik
    George, Jacob
    Schuppan, Detlef
    Gronbaek, Henning
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (03) : 145 - 159
  • [46] The Future of Nonalcoholic Fatty Liver Disease Treatment
    Mazhar, Khurram
    MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (01) : 57 - +
  • [47] How to Diagnose Nonalcoholic Fatty Liver Disease
    de Alwis, Nimantha M. W.
    Anstee, Quentin M.
    Day, Christopher P.
    DIGESTIVE DISEASES, 2016, 34 : 19 - 26
  • [48] Artificial intelligence in nonalcoholic fatty liver disease
    Mahzari, Ali
    EGYPTIAN LIVER JOURNAL, 2022, 12 (01)
  • [49] Recent Epidemiology of Nonalcoholic Fatty Liver Disease
    Murag, Soumya
    Ahmed, Aijaz
    Kim, Donghee
    GUT AND LIVER, 2021, 15 (02) : 206 - 216
  • [50] Role of folate in nonalcoholic fatty liver disease
    Sid, Victoria
    Siow, Yaw L.
    Karmin, O.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2017, 95 (10) : 1141 - 1148
12345